Natco Pharma, 524816, NATCOPHARM Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

16,162.87
14.12
2

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

15,318.37
0.55%
1.75

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

15.57
16.64
17.84

EBITDA CAGR (%)

10 Years
5 Years
3 Years

23.51
29.44
19.20

PAT CAGR (%)

10 Years
5 Years
3 Years

28.39
33.73
38.14

P:E (Median)

8 Years
5 Years
3 Years

17.68
15.52
12.32

P:BV (Average)

8 Years
5 Years
3 Years

3.06
2.77
2.65

EV:EBITDA (Average)

8 Years
5 Years
3 Years

15.22
14.42
8.61

Earnings Forecasts:

(Updated: 08-08-2026)

Description 2026 2027 2028 2029
Adj EPS 77 -29 -20.04 73.62
P/E Ratio 11.73 -31.14 -45.07 12.27
Revenue 23.4 19.85 17.8 4070.12
EBITDA 3083.84 3544.57 3245.9 1490.2
Net Income 723.01 857.89 1014.67 1304.48
ROA 708.71 894.27 956.33 13.92
P/B Ratio -0.35 -0.31 -0.29 1.85
ROE 1.74 1.63 1.51 15.75
FCFF 7.65 8.36 8.8 637.69
FCFF Yield 693.49 326.69 1742.58 4.16
Net Debt 4.53 2.13 11.37 -2484.7
BVPS -2606.67 -2946.07 -3150.5 489.13

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Jun 26 Jun 25 Var% Mar 26 Mar 25 Var% Dec 25 Dec 24 Var% Sep 25 Sep 24 Var%
Net Sales 596.60 1,192.70 -49.98% 608.80 1,157.40 -47.40% 528.80 407.60 29.74% 1,264.30 1,292.60 -2.19%
Expenses 490.60 653.00 -24.87% 516.40 596.20 -13.38% 408.50 378.20 8.01% 711.80 501.90 41.82%
EBITDA 106.00 539.70 -80.36% 92.40 561.20 -83.54% 120.30 29.40 309.18% 552.50 790.70 -30.13%
EBIDTM 17.77% 45.25% 15.18% 48.49% 22.75% 7.21% 43.70% 61.17%
Other Income 48.30 59.60 -18.96% 72.90 62.10 17.39% 55.30 168.00 -67.08% 93.30 51.40 81.52%
Interest 9.60 2.60 269.23% 9.70 8.80 10.23% 8.30 3.40 144.12% 11.70 3.00 290.00%
Depreciation 42.70 53.80 -20.63% 45.60 93.70 -51.33% 42.10 43.70 -3.66% 48.10 42.20 13.98%
PBT 102.00 542.90 -81.21% 110.00 520.80 -78.88% 125.20 150.30 -16.70% 586.00 796.90 -26.47%
Tax 27.40 78.80 -65.23% -99.60 92.70 - 18.30 25.40 -27.95% 85.10 135.80 -37.33%
PAT 74.60 464.10 -83.93% 209.60 428.10 -51.04% 106.90 124.90 -14.41% 500.90 661.10 -24.23%
PATM 12.50% 38.91% 34.43% 36.99% 20.22% 30.64% 39.62% 51.15%
EPS 4.17 25.91 -83.91% 11.70 23.90 -51.05% 5.97 6.97 -14.35% 27.97 36.91 -24.22%

Description Jun 26 Jun 25 Var% Mar 26 Mar 25 Var% Dec 25 Dec 24 Var% Sep 25 Sep 24 Var%
Net Sales 735.20 1,328.90 -44.68% 739.10 1,221.00 -39.47% 647.30 474.80 36.33% 1,363.00 1,371.10 -0.59%
Expenses 548.70 757.90 -27.60% 611.50 672.90 -9.12% 488.60 436.00 12.06% 783.80 566.80 38.29%
EBITDA 186.50 571.00 -67.34% 127.60 548.10 -76.72% 158.70 38.80 309.02% 579.20 804.30 -27.99%
EBIDTM 25.37% 42.97% 17.26% 44.89% 24.52% 8.17% 42.49% 58.66%
Other Income 59.20 61.70 -4.05% 77.80 66.30 17.35% 58.10 176.30 -67.04% 100.00 63.80 56.74%
Interest 13.00 3.20 306.25% 10.90 10.20 6.86% 9.50 4.40 115.91% 13.10 4.10 219.51%
Depreciation 47.10 57.60 -18.23% 50.40 98.30 -48.73% 46.20 47.00 -1.70% 52.40 45.80 14.41%
PBT 185.60 571.90 -67.55% 144.10 505.90 -71.52% 161.10 163.70 -1.59% 613.70 818.20 -24.99%
Tax 63.40 91.60 -30.79% -89.20 99.90 - 20.70 31.30 -33.87% 95.80 141.70 -32.39%
PAT 122.20 480.30 -74.56% 233.30 406.00 -42.54% 140.40 132.40 6.04% 517.90 676.50 -23.44%
PATM 16.62% 36.14% 31.57% 33.25% 21.69% 27.89% 38.00% 49.34%
EPS 11.54 26.85 -57.02% 14.97 22.72 -34.11% 8.46 7.43 13.86% 28.96 37.84 -23.47%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Net Sales 2,998.50 4,094.50 3,568.90 2,351.00 1,767.80 1,653.50 1,790.20 1,986.30 2,091.30 1,958.00 1,021.40 Net Sales Growth -25.97% 14.73% 51.80% 32.99% 6.91% -7.64% -9.87% -5.02% 6.81% 91.70% Cost Of Goods Sold 546.70 545.00 525.80 485.60 502.10 472.30 369.80 317.60 388.50 572.80 256.30 Gross Profit 2,451.80 3,549.50 3,043.10 1,865.40 1,265.70 1,181.20 1,420.40 1,668.70 1,702.80 1,385.20 765.10 GP Margin 81.77% 86.69% 85.27% 79.34% 71.60% 71.44% 79.34% 84.01% 81.42% 70.75% 74.91% Total Expenditure 2,127.30 1,952.40 1,931.90 1,530.20 1,554.80 1,238.30 1,212.20 1,169.80 1,162.90 1,266.00 740.70 Power & Fuel Cost - 93.10 88.90 81.90 76.40 59.40 62.40 59.60 56.10 50.50 43.70 % Of Sales - 2.27% 2.49% 3.48% 4.32% 3.59% 3.49% 3.00% 2.68% 2.58% 4.28% Employee Cost - 515.30 454.90 425.70 410.10 380.00 356.10 340.20 312.20 232.10 171.90 % Of Sales - 12.59% 12.75% 18.11% 23.20% 22.98% 19.89% 17.13% 14.93% 11.85% 16.83% Manufacturing Exp. - 357.70 341.70 269.90 340.80 160.50 230.40 257.50 175.10 162.70 100.60 % Of Sales - 8.74% 9.57% 11.48% 19.28% 9.71% 12.87% 12.96% 8.37% 8.31% 9.85% General & Admin Exp. - 246.80 253.10 155.70 122.50 92.60 111.20 103.90 96.00 78.30 56.90 % Of Sales - 6.03% 7.09% 6.62% 6.93% 5.60% 6.21% 5.23% 4.59% 4.00% 5.57% Selling & Distn. Exp. - 105.60 117.40 59.50 27.00 29.20 22.60 33.50 98.00 128.80 88.40 % Of Sales - 2.58% 3.29% 2.53% 1.53% 1.77% 1.26% 1.69% 4.69% 6.58% 8.65% Miscellaneous Exp. - 88.90 150.10 51.90 75.90 44.30 59.70 57.50 37.00 40.80 88.40 % Of Sales - 2.17% 4.21% 2.21% 4.29% 2.68% 3.33% 2.89% 1.77% 2.08% 2.24% EBITDA 871.20 2,142.10 1,637.00 820.80 213.00 415.20 578.00 816.50 928.40 692.00 280.70 EBITDA Margin 29.05% 52.32% 45.87% 34.91% 12.05% 25.11% 32.29% 41.11% 44.39% 35.34% 27.48% Other Income 269.80 323.50 104.70 109.40 94.60 103.50 123.80 129.80 39.40 13.20 12.90 Interest 39.30 19.60 14.50 8.60 13.30 11.30 20.60 18.80 14.70 17.50 21.90 Depreciation 178.50 220.00 171.90 150.90 138.40 115.20 98.10 80.10 65.50 53.60 50.20 PBT 923.20 2,226.00 1,555.30 770.70 155.90 392.20 583.10 847.40 887.60 634.10 221.50 Tax 31.20 375.60 248.70 133.60 16.80 82.70 108.60 180.30 189.40 139.30 45.00 Tax Rate 3.38% 16.87% 15.99% 17.33% 10.78% 21.09% 18.62% 21.28% 21.34% 21.97% 20.32% PAT 892.00 1,850.40 1,306.60 637.10 139.10 309.50 474.50 667.10 698.20 494.80 176.50 PAT before Minority Interest 892.00 1,850.40 1,306.60 637.10 139.10 309.50 474.50 667.10 698.20 494.80 176.50 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 29.75% 45.19% 36.61% 27.10% 7.87% 18.72% 26.51% 33.59% 33.39% 25.27% 17.28% PAT Growth -46.85% 41.62% 105.09% 358.02% -55.06% -34.77% -28.87% -4.45% 41.11% 180.34% EPS 49.80 103.32 72.95 35.57 7.77 17.28 26.49 37.25 38.98 27.63 9.85

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Net Sales 3,484.60 4,429.50 3,998.80 2,707.10 1,944.80 2,052.10 1,915.00 2,094.50 2,184.80 2,020.20 1,042.30 Net Sales Growth -20.73% 10.77% 47.72% 39.20% -5.23% 7.16% -8.57% -4.13% 8.15% 93.82% Cost Of Goods Sold 605.00 641.50 667.90 583.20 528.40 483.70 354.40 332.70 411.10 599.10 270.60 Gross Profit 2,879.60 3,788.00 3,330.90 2,123.90 1,416.40 1,568.40 1,560.60 1,761.80 1,773.70 1,421.10 771.70 GP Margin 82.64% 85.52% 83.30% 78.46% 72.83% 76.43% 81.49% 84.12% 81.18% 70.34% 74.04% Total Expenditure 2,432.60 2,235.70 2,247.40 1,795.40 1,681.30 1,448.30 1,332.40 1,299.70 1,256.40 1,336.80 776.70 Power & Fuel Cost - 93.10 88.90 81.90 76.40 61.10 62.40 59.60 56.20 50.50 43.70 % Of Sales - 2.10% 2.22% 3.03% 3.93% 2.98% 3.26% 2.85% 2.57% 2.50% 4.19% Employee Cost - 594.50 525.00 486.70 444.80 414.90 375.00 355.90 325.60 243.20 179.80 % Of Sales - 13.42% 13.13% 17.98% 22.87% 20.22% 19.58% 16.99% 14.90% 12.04% 17.25% Manufacturing Exp. - 374.80 368.40 279.60 353.60 291.90 243.30 276.40 182.60 169.70 105.20 % Of Sales - 8.46% 9.21% 10.33% 18.18% 14.22% 12.70% 13.20% 8.36% 8.40% 10.09% General & Admin Exp. - 304.00 313.00 208.80 152.80 116.70 132.60 126.40 105.50 88.10 61.70 % Of Sales - 6.86% 7.83% 7.71% 7.86% 5.69% 6.92% 6.03% 4.83% 4.36% 5.92% Selling & Distn. Exp. - 136.40 153.00 96.10 43.70 34.40 98.10 90.00 136.90 143.20 91.60 % Of Sales - 3.08% 3.83% 3.55% 2.25% 1.68% 5.12% 4.30% 6.27% 7.09% 8.79% Miscellaneous Exp. - 91.40 131.20 59.10 81.60 45.60 66.60 58.70 38.50 43.00 91.60 % Of Sales - 2.06% 3.28% 2.18% 4.20% 2.22% 3.48% 2.80% 1.76% 2.13% 2.31% EBITDA 1,052.00 2,193.80 1,751.40 911.70 263.50 603.80 582.60 794.80 928.40 683.40 265.60 EBITDA Margin 30.19% 49.53% 43.80% 33.68% 13.55% 29.42% 30.42% 37.95% 42.49% 33.83% 25.48% Other Income 295.10 356.70 128.10 128.50 99.00 106.00 107.40 130.20 40.40 13.90 9.60 Interest 46.50 23.90 19.20 14.50 17.70 13.30 21.50 19.30 15.40 18.50 22.90 Depreciation 196.10 235.20 186.80 163.80 142.60 116.90 99.80 81.00 66.20 54.40 50.80 PBT 1,104.50 2,291.40 1,673.50 861.90 202.20 579.60 568.70 824.70 887.20 624.40 201.50 Tax 90.70 408.00 285.20 146.60 32.20 137.20 110.60 182.30 192.00 139.50 47.90 Tax Rate 8.21% 17.81% 17.04% 17.01% 15.92% 23.67% 19.45% 22.11% 21.64% 22.34% 23.77% PAT 1,013.80 1,885.40 1,388.30 715.30 170.00 440.90 460.80 644.40 696.20 486.00 154.90 PAT before Minority Interest 1,013.40 1,883.40 1,388.30 715.30 170.00 442.40 458.10 642.40 695.20 484.90 153.60 Minority Interest -0.40 2.00 0.00 0.00 0.00 -1.50 2.70 2.00 1.00 1.10 1.30 PAT Margin 29.09% 42.56% 34.72% 26.42% 8.74% 21.49% 24.06% 30.77% 31.87% 24.06% 14.86% PAT Growth -40.20% 35.81% 94.09% 320.76% -61.44% -4.32% -28.49% -7.44% 43.25% 213.75% EPS 56.61 105.27 77.52 39.94 9.49 24.62 25.73 35.98 38.87 27.14 8.65

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Shareholder's Funds 7,333.90 5,592.30 4,702.00 4,191.90 4,091.10 3,869.50 3,563.20 3,125.40 1,699.70 1,336.30 Share Capital 35.80 35.80 36.50 36.50 36.50 36.40 36.50 36.90 34.90 34.80 Total Reserves 7,298.10 5,556.50 4,665.50 4,152.00 4,037.00 3,809.50 3,495.80 3,064.30 1,649.40 1,291.80 Non-Current Liabilities 30.40 69.00 116.90 134.90 142.90 117.50 83.10 47.00 37.70 27.90 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 65.60 70.90 85.30 95.70 99.60 90.20 71.00 32.40 21.90 12.50 Current Liabilities 864.60 885.60 569.00 651.20 518.50 659.70 709.80 563.80 609.70 478.50 Trade Payables 225.10 183.30 182.40 141.20 139.50 234.20 201.80 245.40 251.40 270.10 Other Current Liabilities 210.70 204.70 201.40 104.00 111.10 94.20 108.50 131.70 122.80 110.90 Short Term Borrowings 273.10 363.20 159.90 389.00 255.10 312.30 384.50 173.00 220.60 96.00 Short Term Provisions 155.70 134.40 25.30 17.00 12.80 19.00 15.00 13.70 14.90 1.50 Total Liabilities 8,228.90 6,546.90 5,387.90 4,978.00 4,752.50 4,646.70 4,356.10 3,736.20 2,347.10 1,842.70 Net Block 2,516.80 2,286.70 2,233.80 2,174.20 2,005.90 1,574.50 1,214.90 1,015.30 829.00 705.60 Gross Block 3,783.70 3,359.50 3,157.10 2,977.80 2,678.30 2,133.70 1,678.20 1,399.60 1,151.00 975.90 Accumulated Depreciation 1,216.90 1,072.80 923.30 803.60 672.40 559.20 463.30 384.30 322.00 270.30 Non Current Assets 3,540.90 3,136.50 2,893.20 2,810.30 2,584.00 2,406.80 2,088.70 1,682.00 1,312.00 1,051.80 Capital Work in Progress 225.30 133.90 62.80 128.70 223.40 517.80 637.50 480.00 336.20 211.90 Non Current Investment 565.10 577.80 517.60 430.40 294.90 186.10 117.60 101.30 85.90 71.70 Long Term Loans & Adv. 73.00 111.50 78.80 72.40 55.60 124.30 110.40 77.40 54.90 58.40 Other Non Current Assets 160.70 26.60 0.20 4.60 4.20 4.10 8.30 8.00 6.00 4.20 Current Assets 4,688.00 3,410.40 2,494.70 2,167.70 2,168.50 2,239.90 2,267.40 2,054.20 1,035.10 790.90 Current Investments 290.00 163.90 139.90 119.60 42.10 5.00 126.80 48.30 8.90 22.10 Inventories 642.10 596.90 616.00 697.70 769.20 524.40 508.40 425.80 336.90 351.90 Sundry Debtors 1,178.20 1,076.60 793.10 575.60 399.80 536.70 491.60 606.00 468.90 255.80 Cash & Bank 1,856.90 864.90 412.00 100.90 262.80 54.10 262.70 172.10 25.10 40.20 Other Current Assets 720.80 86.10 57.60 78.10 694.60 1,119.70 877.90 802.00 195.30 120.90 Short Term Loans & Adv. 597.40 622.00 476.10 595.80 599.40 1,025.90 769.50 748.80 169.60 95.50 Net Current Assets 3,823.40 2,524.80 1,925.70 1,516.50 1,650.00 1,580.20 1,557.60 1,490.40 425.40 312.40 Total Assets 8,228.90 6,546.90 5,387.90 4,978.00 4,752.50 4,646.70 4,356.10 3,736.20 2,347.10 1,842.70

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Shareholder's Funds 7,607.00 5,853.10 4,873.80 4,263.60 4,121.60 3,773.50 3,489.00 3,072.20 1,649.30 1,295.70 Share Capital 35.80 35.80 36.50 36.50 36.50 36.40 36.50 36.90 34.90 34.80 Total Reserves 7,571.20 5,817.30 4,837.30 4,223.70 4,067.60 3,713.60 3,421.70 3,011.40 1,599.00 1,251.20 Non-Current Liabilities 24.90 61.00 100.50 135.10 142.90 117.80 83.40 47.10 37.70 28.00 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 65.60 70.90 85.30 95.70 99.60 90.20 71.00 32.40 21.90 12.50 Current Liabilities 943.50 972.80 683.10 710.40 525.60 685.30 728.70 592.00 626.50 493.10 Trade Payables 274.90 235.50 263.80 161.80 146.20 255.40 217.00 269.10 262.70 275.60 Other Current Liabilities 238.60 238.90 227.30 126.70 99.50 96.70 109.80 133.40 127.10 114.20 Short Term Borrowings 273.10 363.20 165.00 404.00 265.80 314.20 386.30 173.20 221.60 98.40 Short Term Provisions 156.90 135.20 27.00 17.90 14.10 19.00 15.60 16.30 15.10 4.90 Total Liabilities 8,580.70 6,886.90 5,657.40 5,109.10 4,791.90 4,587.80 4,303.10 3,715.10 2,317.60 1,821.70 Net Block 2,698.00 2,490.80 2,426.90 2,311.80 2,023.20 1,584.40 1,227.20 1,018.60 833.00 710.10 Gross Block 4,015.20 3,603.20 3,375.10 3,126.90 2,702.10 2,148.70 1,694.50 1,407.60 1,158.70 983.30 Accumulated Depreciation 1,267.20 1,112.40 948.20 815.10 678.90 564.30 467.30 389.00 325.70 273.20 Non Current Assets 3,310.70 2,863.40 2,657.10 2,622.40 2,447.10 2,262.20 1,955.90 1,584.40 1,230.30 984.70 Capital Work in Progress 225.40 137.30 64.30 129.50 223.40 518.00 637.60 480.00 336.30 211.80 Non Current Investment 152.80 95.90 87.30 104.40 151.90 83.60 19.90 8.10 0.10 0.10 Long Term Loans & Adv. 73.80 112.70 78.30 72.00 44.30 72.00 62.80 69.60 54.90 58.50 Other Non Current Assets 160.70 26.70 0.30 4.70 4.30 4.20 8.40 8.10 6.00 4.20 Current Assets 5,270.00 4,023.50 3,000.30 2,486.70 2,344.80 2,325.60 2,347.20 2,130.70 1,087.30 837.00 Current Investments 320.80 443.50 305.00 203.70 151.80 28.70 148.70 68.40 32.10 22.10 Inventories 765.80 700.50 742.90 762.00 798.20 558.00 529.00 438.40 348.90 357.30 Sundry Debtors 1,246.60 1,188.90 856.10 620.60 412.90 551.30 506.20 637.50 475.20 261.60 Cash & Bank 2,176.00 952.90 546.30 206.10 283.50 66.00 279.50 183.70 35.80 45.20 Other Current Assets 760.80 99.50 64.40 88.10 698.40 1,121.60 883.80 802.70 195.30 150.80 Short Term Loans & Adv. 625.70 638.20 485.60 606.20 603.70 1,030.00 776.40 749.50 169.50 125.40 Net Current Assets 4,326.50 3,050.70 2,317.20 1,776.30 1,819.20 1,640.30 1,618.50 1,538.70 460.80 343.90 Total Assets 8,580.70 6,886.90 5,657.40 5,109.10 4,791.90 4,587.80 4,303.10 3,715.10 2,317.60 1,821.70

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Cash From Operating Activity 1,662.00 1,196.40 784.40 57.70 183.50 422.50 698.80 476.40 329.80 189.90 PBT 2,226.00 1,555.30 770.70 155.90 392.20 583.10 847.40 887.60 634.10 221.50 Adjustment -20.40 150.90 85.40 118.50 58.40 45.20 12.10 74.40 99.80 81.70 Changes in Working Capital -199.00 -257.80 76.70 -184.20 -190.20 -100.70 14.20 -281.20 -281.70 -68.50 Cash after chg. in Working capital 2,006.60 1,448.40 932.80 90.20 260.40 527.60 873.70 680.80 452.20 234.70 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -344.60 -252.00 -148.40 -32.50 -76.90 -105.10 -174.90 -204.40 -122.40 -44.80 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -1,443.90 -960.50 -436.60 -92.50 -3.20 -165.00 -645.20 -1,131.10 -290.60 -249.30 Net Fixed Assets -515.60 -273.50 -113.40 -204.80 -250.20 -335.80 -436.10 -392.40 -299.40 -303.91 Net Investments -113.40 -84.20 -107.50 -213.00 -145.90 53.30 -94.80 -54.80 -1.00 37.47 Others -814.90 -602.80 -215.70 325.30 392.90 117.50 -114.30 -683.90 9.80 17.14 Cash from Financing Activity -212.40 -237.30 -346.80 35.60 -183.10 -261.10 -52.20 652.00 -45.60 151.40 Net Cash Inflow / Outflow 5.70 -1.40 1.00 0.80 -2.80 -3.60 1.40 -2.70 -6.40 92.00 Opening Cash & Equivalents 5.50 6.90 5.90 5.10 7.90 11.50 10.10 12.80 19.20 -170.00 Closing Cash & Equivalent 11.20 5.50 6.90 5.90 5.10 7.90 11.50 10.10 12.80 -76.80

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Cash From Operating Activity 1,696.80 1,211.60 849.10 46.50 298.80 417.30 668.80 463.60 345.80 112.20 PBT 2,291.40 1,673.50 861.90 202.20 579.60 568.70 824.70 887.20 624.40 208.60 Adjustment -22.30 133.80 102.00 123.90 62.10 54.00 14.30 75.60 100.20 90.50 Changes in Working Capital -199.70 -309.40 62.70 -231.40 -212.90 -97.60 8.60 -294.60 -253.00 -140.70 Cash after chg. in Working capital 2,069.40 1,497.90 1,026.60 94.70 428.80 525.10 847.60 668.20 471.60 158.40 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -372.60 -286.30 -177.50 -48.20 -130.00 -107.80 -178.80 -204.60 -125.80 -46.20 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -1,414.50 -1,032.70 -477.10 -5.30 -103.30 -167.00 -612.20 -1,115.50 -299.40 -175.50 Net Fixed Assets -515.60 -273.50 -113.40 -204.80 -250.20 -335.80 -436.10 -392.40 -299.40 -303.91 Net Investments -113.40 -84.20 -107.50 -213.00 -145.90 53.30 -94.80 -54.80 -1.00 37.47 Others -785.50 -675.00 -256.20 412.50 292.80 115.50 -81.30 -668.30 1.00 90.94 Cash from Financing Activity -210.70 -246.90 -363.00 34.80 -185.70 -250.80 -50.90 650.90 -47.70 154.00 Net Cash Inflow / Outflow 71.60 -68.00 9.00 76.00 9.80 -0.50 5.70 -1.00 -1.30 90.70 Opening Cash & Equivalents 70.40 131.90 111.10 25.80 19.80 28.30 21.70 23.50 24.20 -164.10 Closing Cash & Equivalent 120.00 70.40 131.90 111.10 25.80 19.80 28.30 21.70 23.50 -74.20

Financial Ratios

Consolidated /

Standalone

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Book Value (Rs.) 409.72 312.42 257.64 229.51 223.21 211.31 193.55 168.09 96.52 76.24 ROA 25.05% 21.90% 12.29% 2.86% 6.59% 10.54% 16.49% 22.95% 23.62% 10.90% ROE 28.63% 25.38% 14.33% 3.37% 7.82% 12.86% 20.11% 29.18% 32.87% 16.00% ROCE 33.11% 29.02% 16.51% 3.79% 9.46% 14.85% 23.91% 34.58% 38.71% 18.48% Fixed Asset Turnover 1.19 1.15 0.78 0.65 0.70 0.99 1.41 1.65 1.88 1.20 Receivable days 97.17 90.80 104.18 96.61 101.41 99.38 92.04 93.04 66.04 76.63 Inventory Days 53.39 58.90 100.00 145.29 140.07 99.81 78.34 66.02 62.77 94.81 Payable days 136.76 126.93 121.62 102.03 144.40 66.65 73.69 81.82 79.78 95.04 Cash Conversion Cycle 13.80 22.77 82.56 139.87 97.08 132.54 96.69 77.23 49.02 76.39 Total Debt/Equity 0.04 0.06 0.03 0.09 0.06 0.08 0.11 0.06 0.13 0.08 Interest Cover 114.57 108.26 90.62 12.72 35.71 29.31 46.07 61.38 37.23 11.11

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Book Value (Rs.) 424.97 326.99 267.06 233.44 224.88 206.04 189.49 165.22 93.63 73.91 ROA 24.35% 22.13% 13.29% 3.43% 9.43% 10.30% 16.02% 23.05% 23.43% 9.72% ROE 27.98% 25.88% 15.66% 4.06% 11.27% 12.71% 19.75% 29.70% 33.21% 14.62% ROCE 32.85% 30.08% 18.06% 4.86% 13.99% 14.82% 23.71% 35.28% 39.21% 18.04% Fixed Asset Turnover 1.25 1.24 0.89 0.76 0.86 1.07 1.47 1.72 1.93 1.23 Receivable days 93.30 86.16 93.53 85.10 84.44 93.77 91.36 92.22 65.12 70.27 Inventory Days 56.17 60.81 95.32 128.47 118.77 96.38 77.28 65.25 62.41 89.35 Payable days 145.20 136.43 133.18 106.38 151.52 65.96 72.53 81.42 78.30 85.42 Cash Conversion Cycle 4.27 10.54 55.67 107.20 51.68 124.19 96.11 76.05 49.23 74.21 Total Debt/Equity 0.04 0.06 0.03 0.09 0.06 0.08 0.11 0.06 0.14 0.09 Interest Cover 96.87 88.16 60.44 12.42 44.58 27.45 43.73 58.61 34.75 10.11

Top Investors:

belgrave investment fund

life insurance corporation of india

akash bhanshali

investor education and protection fund (iepf)

llp

Annual Reports:

News Update:

Natco Pharma gets USFDA's tentative approval for Olaparib tablets
20th Jul 2026, 09:05 AM

NATCO will be manufacturing Olaparib tablets and its partner Alembic, would be distributing the product in the U.S
Read More
Natco Pharma completes acquisition of additional 13.25% stake in Adcock Ingram
14th Jul 2026, 13:05 PM

With the completion of this transaction, Natco’s shareholding in Adcock Ingram has increased from 35.75% to 49%
Read More
Natco Pharma gets nod to raise stake in Adcock Ingram to 49%
8th Jul 2026, 15:43 PM

The acquisition is valued at Rs 1,069 crore at the prevailing exchange rate
Read More
Natco Pharma gets nod to invest up to Rs 1,400 crore in NPSAPL
8th Jul 2026, 14:22 PM

The investment is expected to be completed before the end of July of 2026
Read More
Natco Pharma, Lupin receive USFDA’s approval for Eribulin Mesylate Injection
3rd Jun 2026, 12:29 PM

Eribulin Mesylate Injection, 1 mg/2 mL Single-Dose Vials is the bioequivalent to the RLD Halaven Injection of Eisai, Inc
Read More
Natco Pharma reports 34% fall in Q4 consolidated net profit
30th May 2026, 15:00 PM

Consolidated total income of the company decreased by 36.54% at Rs 816.90 crore for Q4FY26
Read More
Natco Pharma - Quarterly Results
30th May 2026, 00:00 AM

Read More

Natco Pharma Ltd.

Pharmaceuticals & Drugs - Global

BSE: 524816 | NSE: NATCOPHARM

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update:

Natco Pharma Ltd.

Pharmaceuticals & Drugs - Global

BSE: 524816 | NSE: NATCOPHARM

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update: